{"url_path":"/sec/ino/8-k/2026-05-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001193125-26-232524-index.html","accession_number":"0001193125-26-232524","cik":"0001055726","ticker":"INO","issuer_name":"INOVIO PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001193125-26-232524-index.html","primary_entity_key":"0001055726","primary_entity_name":"INOVIO PHARMACEUTICALS, INC."},"word_count":83,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \nExhibit Description\n\n 3.1\n  \n[Amendment to Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc., dated May 19, 2026.](d138309dex31.htm)\n\n104\n  \nCover Page Interactive Data File (formatted as inline XBRL).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nINOVIO PHARMACEUTICALS, INC.\n\nDate: May 20, 2026\n \n\n \n\n \n\n/s/ Peter Kies\n\n \n\n \n\n \nPeter Kies\n\n \n\n \n\n \nChief Financial Officer"}